Q4 2025 Fennec Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Fennec Pharmaceuticals Inc (FENC) achieved record net product sales of $44.6 million in 2025, a significant increase from $29.6 million in 2024.
- The company successfully expanded its customer-facing team and increased its reach in the adolescent and young adult (AYA) market.
- Fennec Pharmaceuticals Inc (FENC) strengthened its financial health by raising over $42 million in net proceeds, allowing for the full redemption of its debt.
- The FENIC-HEARS patient support program achieved record performance in Q4 2025, with high conversion rates and increased patient enrollments.
- The company made significant progress in advancing its clinical evidence strategy, including new studies and collaborations with leading oncology centers.
- Selling and marketing expenses increased to $6.1 million in Q4 2025 from $3.9 million in the same period in 2024, due to increased payroll and marketing expenses.
- General and administrative expenses rose to $8.9 million in Q4 2025 from $4.2 million in Q4 2024, driven by higher intellectual property legal expenses and increased payroll.
- The company anticipates cash operating expenses to grow from approximately $35 million in 2025 to approximately $50 million in 2026, due to commercial expansion and awareness initiatives.
- There is ongoing concern among physicians about whether sodium thiosulfate could reduce cisplatin's anti-tumor activity, although long-term data is helping to alleviate these concerns.
- The company faces challenges in expanding its market presence internationally, with ongoing efforts to establish partnerships and regulatory approvals in regions like Japan.
Good morning, ladies and gentlemen. Welcome to Fennec Pharmaceuticals' fourth-quarter and full-year 2025 earnings and corporate update conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.
Now, I'd like to turn the conference over to Fennec's Chief Financial Officer, Robert Andrade.
Thank you, operator, and good morning, everyone. Thank you for joining us today. We are pleased to host Fennec Pharmaceuticals' fourth-quarter and full-year 2025 earnings conference call, during which we will review our financial results as well as provide a general business update. Towards the end of the call, we will conduct a Q&A session hosted by myself, starting with frequent questions that the company receives from investors, followed by our traditional open Q&A session.
Joining me from Fennec this morning is our Chief Executive Officer and Board Member, Jeff Hackman. I am also pleased to welcome our Chief Medical Officer, Dr. Pierre
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
